These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1583349)

  • 21. Simultaneous chronic myeloid leukemia and chronic lymphocytic leukemia.
    Buda-Okreglak EM; Cordaro DV
    Blood; 2011 May; 117(20):5279. PubMed ID: 21744517
    [No Abstract]   [Full Text] [Related]  

  • 22. CA 15.3 with urinary calcium excretion is useful in the diagnosis and monitoring of bone metastases from breast cancer.
    Yadav GC; Rao A; Motawy MM; Safadi N; Ahmed MJ
    Int J Biol Markers; 1993; 8(4):208-14. PubMed ID: 8138660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating CA 549 and other associated antigens in breast cancer patients.
    Pavesi F; Lotzniker M; Scarabelli M; Mauro E; Visconti G; Nicolato E; Moratti R
    Oncology; 1994; 51(1):18-21. PubMed ID: 8265097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
    Safi F; Kohler I; Röttinger E; Beger H
    Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum and cytosolic levels of CA549 in breast cancer patients.
    Correale M; Abbate I; Dragone CD; Tedone T; Gargano G; Catino A; Paradiso A; Addabbo L; Musci MD; De Lena M
    Clin Exp Obstet Gynecol; 1993; 20(4):264-7. PubMed ID: 8281711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3.
    van Dalen A
    Tumour Biol; 1992; 13(1-2):10-7. PubMed ID: 1589693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Report of BACR workshop on monoclonal antibodies in breast and ovarian cancer, Brasenose College, Oxford March 17-19th 1991.
    Leonard RC; Fisken J; Roulston JE
    Br J Cancer; 1991 Oct; 64(4):796-7. PubMed ID: 1911231
    [No Abstract]   [Full Text] [Related]  

  • 28. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.
    Steger GG; Mader R; Derfler K; Moser K; Dittrich C
    Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variability of tumor markers in the follow-up of patients radically resected for breast cancer.
    Gion M; Cappelli G; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M
    Tumour Biol; 1993; 14(6):325-33. PubMed ID: 8265978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast cancer and clinical utility of CA 15-3 and CEA.
    Jäger W; Krämer S; Palapelas V; Norbert L
    Scand J Clin Lab Invest Suppl; 1995; 221():87-92. PubMed ID: 7652494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques.
    Zanco P; Rota G; Sportiello V; Borsato N; Ferlin G
    Int J Biol Markers; 1989; 4(2):103-5. PubMed ID: 2768888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum and immunohistochemical studies of NCC-ST-439 in breast cancer.
    Narita T; Funahashi H; Satoh Y; Imai T; Takagi H
    J Surg Oncol; 1993 Sep; 54(1):5-8. PubMed ID: 8377506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.
    Colomer R; Ruibal A; Salvador L
    Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative and longitudinal serum levels of CA 125 and CA 15.3 in patients with breast cancer.
    Omar YT; Behbehani AE; al-Naqeeb N; Motawy MM; Foudeh MO; Awwad AH; Nasralla MY; Szymendera JJ
    Int J Biol Markers; 1989; 4(2):81-6. PubMed ID: 2768892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum level of cryptic tumor antigens in breast cancer patients as determined by two monoclonal antibodies (M85/F36) and its comparison with CA 15-3.
    Chu TM; Constantine R; Nemoto T
    J Clin Lab Anal; 1989; 3(5):267-72. PubMed ID: 2681619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases?
    Jäger W; Kissing A; Cilaci S; Melsheimer R; Lang N
    Br J Cancer; 1994 Sep; 70(3):493-5. PubMed ID: 8080736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CA 549 and SP2: new tumor markers in breast cancer.
    Torres M; Jiménez-Heffernan A; García A; Valverde A; Mateo A
    Int J Biol Markers; 1990; 5(2):97-8. PubMed ID: 2283484
    [No Abstract]   [Full Text] [Related]  

  • 38. Mucin-like carcinoma-associated antigen (MCA) in breast cancer: clinical experience at the National Cancer Institute of Milan.
    Seregni E; Crippa F; Botti C; Bellotti MG; Bogni A; Pizzichetta M; Bombardieri E
    Int J Biol Markers; 1993; 8(2):124-9. PubMed ID: 8366295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical use of tumor markers in the postoperative management of breast cancer patients: new concepts.
    Nicolini A; Carpi A; Ferrari P; Anselmi L
    Int J Biol Markers; 1997; 12(4):181-6. PubMed ID: 9582609
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3.
    Miserez AR; Günes I; Müller-Brand J; Walther E; Fridrich R; Mäcke H
    Eur J Cancer; 1991; 27(2):126-31. PubMed ID: 1827273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.